A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma
A phase 3 trial testing Rocbrutinib in mantle cell lymphoma, now recruiting.
Overview
A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma is a phase 3 interventional study registered as NCT07377578, led by Guangzhou Lupeng Pharmaceutical, and recruiting when checked on 2026-09-11. Official title: A Randomised, Open-label, Multicenter, Phase III Clinical Study Comparing Rocbrutinib Monotherapy Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL) (PRIME Study). Planned enrolment is 394 participants (estimated). The study started in 2026-02-05 and primary completion is expected in 2031-05-30. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
Shares Rocbrutinib and the tag ctgov-ingest.
- TreatmentCTX112
Shares Mantle cell lymphoma and the tag ctgov-ingest.
- TreatmentICP-248
Shares Mantle cell lymphoma and the tag ctgov-ingest.
- TreatmentZamtocabtagene autoleucel
Shares Mantle cell lymphoma and the tag ctgov-ingest.